{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T05:02:13Z","timestamp":1790226133331,"version":"4.1.0"},"reference-count":131,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:00Z","timestamp":1790208000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer and the one with the fewest therapeutic targets. The application of machine learning (ML) in TNBC research is becoming increasingly widespread; however, systematic bibliometric studies focusing on this rapidly evolving interdisciplinary field are still lacking.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study systematically searched the Web of Science Core Collection and Scopus databases for relevant literature on the application of ML in the field of TNBC published between January 2011 and January 2026. These publications were analyzed using VOSviewer, CiteSpace, and the R\/Bibliometrix package. An independent external validation was conducted using the same search strategy in the PubMed database. Additionally, clinical trials and randomized controlled trials were identified through PubMed to quantify the clinical translation gap in this field.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We conducted a bibliometric analysis of 394 publications and found that global publication output exhibits a nonlinear growth trend. China ranked first in publication volume with 180 papers, while the United States ranked first in academic influence with an average of 39.09 citations per paper; the collaboration network revealed a global pattern with China and the United States as dual hubs. Co-occurrence analysis of keywords identified six major thematic clusters, broadly corresponding to three domains: disease understanding, methodological innovation, and clinical translation. Citation emergence analysis revealed that \u201cdeep learning,\u201d \u201cradiomics,\u201d and \u201ctumor-infiltrating lymphocytes\u201d represent the most robust emerging frontiers at present. Cluster analysis of co-cited literature identified three dominant research themes: prognostic prediction models, radiomic diagnosis, and multi-omics integration. External validation results from PubMed showed high consistency with the main analysis; however, the clinical translation gap analysis revealed a 16:1 retrospective-validation-to-development ratio (24 retrospective validation studies versus 394 development studies) and a 44:1 prospective-trial-to-development ratio (9 registered trials versus 394 development studies). No prospective interventional trials were identified.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Research on machine learning in the field of triple-negative breast cancer (TNBC) is currently undergoing rapid expansion, with current research hotspots centered on radiomics, deep learning, and the discovery of multi-omics biomarkers. However, clinical validation remains scarce: only 24 retrospective validation studies (6.1%) and 9 registered trials (2.3%) were identified relative to 394 computational development studies. Our bibliometric analysis reveals a substantial gap between computational publication output and clinical validation evidence, and the research paradigm remains primarily methodology-driven rather than clinically anchored. Multicenter, prospective clinical trials with patient-centered endpoints are needed to bridge this structural translation gap.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1912317","type":"journal-article","created":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T04:36:35Z","timestamp":1790224595000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["The translational chasm in machine learning for triple-negative breast cancer: a quantitative landscape assessment"],"prefix":"10.3389","volume":"16","author":[{"given":"Nadire","family":"Yiming","sequence":"first","affiliation":[{"name":"Department of Breast Surgery, The Affiliated Tumor Hospital of Xinjiang Medical University","place":["Urumqi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yilina","family":"Saibaidoula","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, The Affiliated Tumor Hospital of Xinjiang Medical University","place":["Urumqi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kadeyanmu","family":"Abulimiti","sequence":"additional","affiliation":[{"name":"Department of Cardiac Surgery, The First Affiliated Hospital of Xinjiang Medical University","place":["Urumqi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianghua","family":"Ou","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, The Affiliated Tumor Hospital of Xinjiang Medical University","place":["Urumqi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA: A Cancer J For Clin"},{"key":"B2","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.breast.2022.08.010","article-title":"Current and future burden of breast cancer: Global statistics for 2020 and 2040","volume":"66","author":"Arnold","year":"2022","journal-title":"Breast"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21863","article-title":"Breast cancer statistics 2024","volume":"74","author":"Giaquinto","year":"2024","journal-title":"CA: A Cancer J For Clin"},{"key":"B4","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/s41571-021-00565-2","article-title":"Treatment landscape of triple-negative breast cancer\u2014expanded options, evolving needs","volume":"19","author":"Bianchini","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1146\/annurev-pathol-042420-093238","article-title":"Pathogenesis of triple-negative breast cancer","volume":"17","author":"Derakhshan","year":"2022","journal-title":"Annu Rev Pathology: Mech Dis"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics16050671","article-title":"Artificial intelligence in triple-negative breast cancer: Applications in diagnosis, treatment response, and prognosis","volume":"16","author":"Fu","year":"2026","journal-title":"Diagnostics"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2022.836417","article-title":"Triple-negative breast cancer: A brief review about epidemiology, risk factors, signaling pathways, treatment and role of artificial intelligence","volume":"9","author":"Almansour","year":"2022","journal-title":"Front Mol Biosci"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.12215","article-title":"Artificial intelligence for assisting cancer diagnosis and treatment in the era of precision medicine","volume":"41","author":"Chen","year":"2021","journal-title":"Cancer Commun"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03714-7","article-title":"Artificial intelligence improves breast cancer detection in mammography screening","volume":"31","author":"Eisemann","year":"2025","journal-title":"Nat Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.848271","article-title":"BUSnet: A deep learning model of breast tumor lesion detection for ultrasound images","volume":"12","author":"Li","year":"2022","journal-title":"Front Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-023-01687-4","article-title":"Deep learning applications to breast cancer detection by magnetic resonance imaging: A literature review","volume":"25","author":"Adam","year":"2023","journal-title":"Breast Cancer Res"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.34133\/bmef.0212","article-title":"Multiomics machine learning to predict neoadjuvant chemotherapy outcome and relapse of breast cancer","volume":"7","author":"Wang","year":"2026","journal-title":"BME Front"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1459914","article-title":"Construction of a nomogram prediction model for the pathological complete response after neoadjuvant chemotherapy in breast cancer: A study based on ultrasound and clinicopathological features","volume":"15","author":"Ni","year":"2025","journal-title":"Front Oncol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1038\/s41540-026-00721-3","article-title":"Biomarker identification of triple negative breast cancer subtypes using machine learning","volume":"12","author":"Mohammad","year":"2026","journal-title":"NPJ Syst Biol Appl"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.softx.2025.102098","article-title":"BibexPy: Harmonizing the bibliometric symphony of scopus and web of science","volume":"30","author":"Kara","year":"2025","journal-title":"SoftwareX"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1002\/asi.20317","article-title":"CiteSpace II: Detecting and visualizing emerging trends and transient patterns in scientific literature","volume":"57","author":"Chen","year":"2006","journal-title":"J Am Soc For Inf Sci Technol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1515\/jdis-2017-0006","article-title":"Science mapping: A systematic review of the literature","volume":"2","author":"Chen","year":"2017","journal-title":"J Data Inf Sci"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s11192-009-0146-3","article-title":"Software survey: VOSviewer, a computer program for bibliometric mapping","volume":"84","author":"Van Eck","year":"2010","journal-title":"Scientometrics"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.joi.2017.08.007","article-title":"Bibliometrix: An r-tool for comprehensive science mapping analysis","volume":"11","author":"Aria","year":"2017","journal-title":"J Informetrics"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph17062078","article-title":"Triple-negative breast cancer: A review of conventional and advanced therapeutic strategies","volume":"17","author":"Medina","year":"2020","journal-title":"Int J Environ Res Public Health"},{"key":"B21","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1186\/s13046-019-1443-1","article-title":"Recent advances in nanotheranostics for triple negative breast cancer treatment","volume":"38","author":"Thakur","year":"2019","journal-title":"J Exp Clin Cancer Res"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2018.08.039","article-title":"A structured tumor-immune microenvironment in triple negative breast cancer revealed by multiplexed ion beam imaging","volume":"174","author":"Keren","year":"2018","journal-title":"Cell"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.2004155","article-title":"The receptor AXL diversifies EGFR signaling and limits the response to EGFR-targeted inhibitors in triple-negative breast cancer cells","volume":"6","author":"Meyer","year":"2013","journal-title":"Sci Signaling"},{"key":"B24","doi-asserted-by":"publisher","first-page":"4867","DOI":"10.1038\/s41467-021-25189-z","article-title":"ICAM1 initiates CTC cluster formation and trans-endothelial migration in lung metastasis of breast cancer","volume":"12","author":"Taftaf","year":"2021","journal-title":"Nat Commun"},{"key":"B25","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1186\/s13046-018-1002-1","article-title":"Classification of triple-negative breast cancers based on immunogenomic profiling","volume":"37","author":"He","year":"2018","journal-title":"J Exp Clin Cancer Res"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijsu.2022.106936","article-title":"Leveraging diverse cell-death patterns to predict the prognosis and drug sensitivity of triple-negative breast cancer patients after surgery","volume":"107","author":"Zou","year":"2022","journal-title":"Int J Surg"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/s41422-022-00614-0","article-title":"Comprehensive metabolomics expands precision medicine for triple-negative breast cancer","volume":"32","author":"Xiao","year":"2022","journal-title":"Cell Res"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-018-0185-8","article-title":"A machine learning approach to radiogenomics of breast cancer: A study of 922 subjects and 529 dce-mri features","volume":"119","author":"Saha","year":"2018","journal-title":"Br J Cancer"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-021-08271-4","article-title":"Predicting the molecular subtype of breast cancer and identifying interpretable imaging features using machine learning algorithms","volume":"32","author":"Ma","year":"2022","journal-title":"Eur Radio"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2026.1743315","article-title":"Development and validation of an interpretable ensemble model for predicting androgen receptor status in triple-negative breast cancer: a multi-center study","volume":"16","author":"Ruan","year":"2026","journal-title":"Front Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1153261","article-title":"Multimodality MRI radiomics analysis of TP53 mutations in triple negative breast cancer","volume":"13","author":"Sun","year":"2023","journal-title":"Front Oncol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-022-04142-7","article-title":"Combined diagnosis of multiparametric mri-based deep learning models facilitates differentiating triple-negative breast cancer from fibroadenoma magnetic resonance bi-rads 4 lesions","volume":"149","author":"Yin","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2026.1654953","article-title":"Prognostic prediction model for triple-negative breast cancer using artificial intelligence and ultrasound radiomics","volume":"16","author":"Zilalan","year":"2026","journal-title":"Front Oncol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-021-05489-8","article-title":"Co-clinical fdg-pet radiomic signature in predicting response to neoadjuvant chemotherapy in triple-negative breast cancer","volume":"49","author":"Roy","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejrad.2021.110095","article-title":"Radiomics features based on automatic segmented MRI images: Prognostic biomarkers for triple-negative breast cancer treated with neoadjuvant chemotherapy","volume":"146","author":"Ma","year":"2022","journal-title":"Eur J Radiol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmpb.2025.109130","article-title":"Prediction of neoadjuvant therapy response to HER2-positive and triple-negative breast cancer: a multicenter proof-of-concept study","volume":"273","author":"Fu","year":"2026","journal-title":"Comput Methods Programs BioMed"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1038\/s41598-023-27518-2","article-title":"Prediction of pathologic complete response to neoadjuvant systemic therapy in triple negative breast cancer using deep learning on multiparametric MRI","volume":"13","author":"Zhou","year":"2023","journal-title":"Sci Rep"},{"key":"B38","doi-asserted-by":"publisher","first-page":"23065","DOI":"10.1038\/s41598-024-74276-w","article-title":"Deep-learning based discrimination of pathologic complete response using MRI in HER2-positive and triple-negative breast cancer","volume":"14","author":"Kim","year":"2024","journal-title":"Sci Rep"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1797753","article-title":"AI-driven spatial analysis of tumor-infiltrating lymphocytes predicts chemo-immunotherapy response in triple-negative breast cancer","volume":"17","author":"Liang","year":"2026","journal-title":"Front Immunol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2025.103557","article-title":"Development and validation of an artificial intelligence system for triple-negative breast cancer identification and prognosis prediction: a multicentre retrospective study","volume":"89","author":"Zhang","year":"2025","journal-title":"EClinicalMedicine"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102928","article-title":"The analytical and clinical validity of AI algorithms to score Tils in Tnbc: Can we use different machine learning models interchangeably","volume":"78","author":"Vidal","year":"2024","journal-title":"EClinicalMedicine"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-0325","article-title":"An open-source, automated tumor-infiltrating lymphocyte algorithm for prognosis in triple-negative breast cancer","volume":"27","author":"Bai","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2026.1798015","article-title":"The role of AI-driven decision support in immunotherapy for predicting pathological complete response in triple-negative breast cancer","volume":"16","author":"Lu","year":"2026","journal-title":"Front Oncol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1002\/path.6274","article-title":"Automated tumor immunophenotyping predicts clinical benefit from anti-PD-L1 immunotherapy","volume":"263","author":"Li","year":"2024","journal-title":"J Pathol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1544348","article-title":"Construction of a stromal cell-related prognostic signature based on a 101-combination machine learning framework for predicting prognosis and immunotherapy response in triple-negative breast cancer","volume":"16","author":"Li","year":"2025","journal-title":"Front Immunol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1561563","article-title":"Analysis of prognostic factors and nomogram construction for postoperative survival of triple-negative breast cancer","volume":"16","author":"Wang","year":"2025","journal-title":"Front Immunol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.995555","article-title":"Systematic evaluation of tumor microenvironment and construction of a machine learning model to predict prognosis and immunotherapy efficacy in triple-negative breast cancer based on data mining and sequencing validation","volume":"13","author":"Gou","year":"2022","journal-title":"Front Pharmacol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-0075","article-title":"Prediction of lymph node metastasis in breast cancer by gene expression and clinicopathological models: Development and validation within a population-based cohort","volume":"25","author":"Dihge","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2026.1874031","article-title":"Machine learning-based prognostic model for triple-negative breast cancer with axillary lymph node metastasis","volume":"16","author":"Huang","year":"2026","journal-title":"Front Oncol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.clbc.2025.07.027","article-title":"Prediction of overall and relapse-free survival in triple-negative breast cancer patients through machine learning-based clustering on clinical data","volume":"25","author":"Alzate-Granados","year":"2025","journal-title":"Clin Breast Cancer"},{"key":"B51","doi-asserted-by":"publisher","first-page":"30248","DOI":"10.1038\/s41598-025-16331-8","article-title":"Deep learning for survival prediction in triple-negative breast cancer: development and validation in real-world cohorts","volume":"15","author":"Xu","year":"2025","journal-title":"Sci Rep"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1002\/1878-0261.12850","article-title":"High-throughput proteomics of breast cancer interstitial fluid: identification of tumor subtype-specific serologically relevant biomarkers","volume":"15","author":"Terkelsen","year":"2021","journal-title":"Mol Oncol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.115.001593","article-title":"Machine learning in medicine","volume":"132","author":"Deo","year":"2015","journal-title":"Circulation"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1172\/JCI45014","article-title":"Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies","volume":"121","author":"Lehmann","year":"2011","journal-title":"J Clin Invest"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-0432","article-title":"Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer","volume":"21","author":"Burstein","year":"2015","journal-title":"Clin Cancer Res"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.2020191145","article-title":"The image biomarker standardization initiative: standardized quantitative radiomics for high-throughput image-based phenotyping","volume":"295","author":"Zwanenburg","year":"2020","journal-title":"Radiology"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/S2589-7500(20)30218-1","article-title":"Reporting guidelines for clinical trial reports for interventions involving artificial intelligence: the CONSORT-AI extension","volume":"2","author":"Liu","year":"2020","journal-title":"Lancet Digital Health"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/S2589-7500(20)30219-3","article-title":"Guidelines for clinical trial protocols for interventions involving artificial intelligence: the SPIRIT-AI extension","volume":"2","author":"Rivera","year":"2020","journal-title":"Lancet Digital Health"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-048008","article-title":"Protocol for development of a reporting guideline (TRIPOD-AI) and risk of bias tool (PROBAST-AI) for diagnostic and prognostic prediction model studies based on artificial intelligence","volume":"11","author":"Collins","year":"2021","journal-title":"BMJ Open"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01772-9","article-title":"Reporting guideline for the early stage clinical evaluation of decision support systems driven by artificial intelligence: DECIDE-AI","volume":"28","author":"Vasey","year":"2022","journal-title":"Nat Med"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/j.chembiol.2019.03.011","article-title":"Phenotypic screening combined with machine learning for efficient identification of breast cancer-selective therapeutic targets","volume":"26","author":"Gautam","year":"2019","journal-title":"Cell Chem Biol"},{"key":"B62","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s41523-020-0154-2","article-title":"Report on computational assessment of tumor infiltrating lymphocytes from the international immuno-oncology biomarker working group","volume":"6","author":"Amgad","year":"2020","journal-title":"NPJ Breast Cancer"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1021\/acssensors.0c00329","article-title":"Machine learning for precision breast cancer diagnosis and prediction of the nanoparticle cellular internalization","volume":"5","author":"Alafeef","year":"2020","journal-title":"ACS Sens"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2025.1630408","article-title":"A decade of review in global regulation and research of artificial intelligence medical devices (2015\u20132025)","volume":"12","author":"Zhang","year":"2025","journal-title":"Front Med"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/S2589-7500(21)00076-5","article-title":"Continual learning in medical devices: FDA's action plan and beyond","volume":"3","author":"Vokinger","year":"2021","journal-title":"Lancet Digital Health"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1145\/3473856.3474005","article-title":"Medical artificial intelligence: the european legal perspective","volume":"64","author":"St\u00f6ger","year":"2021","journal-title":"Commun ACM"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1016\/S2589-7500(20)30292-2","article-title":"Approval of artificial intelligence and machine learning-based medical devices in the USA and europe (2015\u201320): a comparative analysis","volume":"3","author":"Muehlematter","year":"2021","journal-title":"Lancet Digital Health"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3896","article-title":"Triple-negative breast cancer in african-american women: disparities versus biology","volume":"15","author":"Dietze","year":"2015","journal-title":"Nat Rev Cancer"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-055735","article-title":"Triple-negative breast cancer prevalence in africa: a systematic review and meta-analysis","volume":"12","author":"Hercules","year":"2022","journal-title":"BMJ Open"},{"key":"B70","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s13073-026-01665-3","article-title":"African ancestry and risk variants associated with triple-negative breast cancer susceptibility in african american women","volume":"18","author":"Jia","year":"2026","journal-title":"Genome Med"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1002\/jso.28088","article-title":"Disparities in triple negative breast cancer among hispanic population living in latin america versus the United States","volume":"131","author":"De la Cruz Ku","year":"2025","journal-title":"J Surg Oncol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1200\/GO.21.00082","article-title":"Prevalence and mortality of triple-negative breast cancer in west africa: biologic and sociocultural factors","volume":"7","author":"Nwagu","year":"2021","journal-title":"JCO Global Oncol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph22081220","article-title":"Precision medicine for cancer and health equity in latin america: generating understanding for policy and health system shaping","volume":"22","author":"Gonz\u00e1lez","year":"2025","journal-title":"Int J Environ Res Public Health"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.05.355","article-title":"First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis","volume":"32","author":"Emens","year":"2021","journal-title":"Ann Oncol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01409","article-title":"Final results from the randomized phase III ASCENT clinical trial in metastatic triple-negative breast cancer and association of outcomes by human epidermal growth factor receptor 2 and trophoblast cell surface antigen 2 expression","volume":"42","author":"Bardia","year":"2024","journal-title":"J Clin Oncol"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(25)00463-2","article-title":"The Lucerne toolbox 3: digital health and artificial intelligence to optimise the patient journey in early breast cancer-a multidisciplinary consensus","volume":"26","author":"Pfob","year":"2025","journal-title":"Lancet Oncol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1016\/j.landig.2025.100921","article-title":"Label-efficient computational tumour infiltrating lymphocyte assessment in breast cancer (ECTIL): multicentre validation in 2340 patients with breast cancer","volume":"7","author":"Schirris","year":"2025","journal-title":"Lancet Digital Health"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1016\/S2589-7500(23)00153-X","article-title":"Artificial intelligence for breast cancer detection in screening mammography in Sweden: a prospective, population-based, paired-reader, non-inferiority study","volume":"5","author":"Dembrower","year":"2023","journal-title":"Lancet Digital Health"},{"key":"B79","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s41523-024-00629-3","article-title":"Automated mitotic spindle hotspot counts are highly associated with clinical outcomes in systemically untreated early-stage triple-negative breast cancer","volume":"10","author":"Leon-Ferre","year":"2024","journal-title":"NPJ Breast Cancer"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1007\/s13402-019-00445-z","article-title":"Deep learning and manual assessment show that the absolute mitotic count does not contain prognostic information in triple negative breast cancer","volume":"42","author":"Balkenhol","year":"2019","journal-title":"Cell Oncol"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1038\/s41374-019-0275-0","article-title":"Deep learning assisted mitotic counting for breast cancer","volume":"99","author":"Balkenhol","year":"2019","journal-title":"Lab Invest"},{"key":"B82","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.breast.2021.02.007","article-title":"Optimized tumour infiltrating lymphocyte assessment for triple negative breast cancer prognostics","volume":"56","author":"Balkenhol","year":"2021","journal-title":"Breast"},{"key":"B83","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1002\/path.6155","article-title":"Pitfalls in machine learning-based assessment of tumor-infiltrating lymphocytes in breast cancer: a report of the international immuno-oncology biomarker working group on breast cancer","volume":"260","author":"Thagaard","year":"2023","journal-title":"J Pathol"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/2140465","article-title":"Radiomics analysis based on automatic image segmentation of dce-mri for predicting triple-negative and nontriple-negative breast cancer","volume":"2021","author":"Ma","year":"2021","journal-title":"Comput Math Methods Med"},{"key":"B85","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/s12910-024-01135-8","article-title":"Exploring barriers and ethical challenges to medical data sharing: perspectives from chinese researchers","volume":"25","author":"Li","year":"2024","journal-title":"BMC Med Ethics"},{"key":"B86","doi-asserted-by":"publisher","first-page":"127294","DOI":"10.1016\/j.saa.2025.127294","article-title":"Raman imaging uncovers ebracteolatain a's subtype-selective metabolic reprogramming in luminal versus triple-negative breast cancer cells","volume":"349","author":"Li","year":"2025","journal-title":"Spectrochimica Acta Part A Mol Biomolecular Spectrosc"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1021\/acs.analchem.5c02233","article-title":"New chemotherapeutic approaches to treatment of mesenchymal triple-negative breast cancer-sensitive and resistant to cisplatin: assessment of cellular response by vibrational microspectroscopy","volume":"97","author":"Martins","year":"2025","journal-title":"Anal Chem"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-04278-5","article-title":"Multi-omic machine learning predictor of breast cancer therapy response","volume":"601","author":"Sammut","year":"2022","journal-title":"Nature"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2025.103892","article-title":"Multimodal data integration in early-stage breast cancer","volume":"80","author":"Llinas-Bertran","year":"2025","journal-title":"Breast"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btz342","article-title":"Deep learning with multimodal representation for pancancer prognosis prediction","volume":"35","author":"Cheerla","year":"2019","journal-title":"Bioinformatics"},{"key":"B91","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s13059-017-1215-1","article-title":"Multi-omics approaches to disease","volume":"18","author":"Hasin","year":"2017","journal-title":"Genome Biol"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.11.016","article-title":"Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"35","author":"Loibl","year":"2024","journal-title":"Ann Oncol"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu450","article-title":"The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014","volume":"26","author":"Salgado","year":"2015","journal-title":"Ann Oncol"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1809615","article-title":"Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer","volume":"379","author":"Schmid","year":"2018","journal-title":"N Engl J Med"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910549","article-title":"Pembrolizumab for early triple-negative breast cancer","volume":"382","author":"Schmid","year":"2020","journal-title":"N Engl J Med"},{"key":"B96","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1186\/s12877-022-02936-5","article-title":"The impact of chemotherapy and survival prediction by machine learning in early elderly triple negative breast cancer (etnbc): a population based study from the Seer database","volume":"22","author":"Huang","year":"2022","journal-title":"BMC Geriatrics"},{"key":"B97","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1186\/s12885-025-13635-w","article-title":"Integrating ultrasound radiomics and clinicopathological features for machine learning-based survival prediction in patients with nonmetastatic triple-negative breast cancer","volume":"25","author":"Wenwen","year":"2025","journal-title":"BMC Cancer"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1016\/j.acra.2026.01.016","article-title":"A multimodal fusion model of radiomics and deep learning integrating the tumor microenvironment accurately predicts pathological complete response in breast cancer","volume":"33","author":"Hong","year":"2026","journal-title":"Acad Radiol"},{"key":"B99","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/s41698-025-01256-2","article-title":"Longitudinal mri-based deep learning model for predicting pathological complete response in breast cancer: a multicenter, retrospective cohort study","volume":"10","author":"Huang","year":"2026","journal-title":"NPJ Precis Oncol"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1148\/ryai.230137","article-title":"Impact of a categorical AI system for digital breast tomosynthesis on breast cancer interpretation by both general radiologists and breast imaging specialists","volume":"6","author":"Kim","year":"2024","journal-title":"Radiology: Artif Intell"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-023-09461-y","article-title":"Artificial intelligence in breastscreen Norway: A retrospective analysis of a cancer-enriched sample including 1254 breast cancer cases","volume":"33","author":"Koch","year":"2023","journal-title":"Eur Radio"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02625-9","article-title":"Prospective implementation of ai-assisted ScreenTrustCAD reading to improve early detection of breast cancer","volume":"29","author":"Ng","year":"2023","journal-title":"Nat Med"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.243824","article-title":"Posttreatment MRI to predict pathologic complete response of triple-negative breast cancer to neoadjuvant chemoimmunotherapy","volume":"316","author":"Ramtohul","year":"2025","journal-title":"Radiology"},{"key":"B104","doi-asserted-by":"publisher","first-page":"116222","DOI":"10.1016\/j.ejca.2026.116222","article-title":"Chemo-praidict breast: A deep learning solution for predicting residual disease on biopsies of breast cancer patients treated with neoadjuvant chemotherapy","volume":"234","author":"Valderrama","year":"2026","journal-title":"Eur J Cancer"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.20892\/j.issn.2095-3941.2025.0655","article-title":"The role of radiomics in predicting the response to neoadjuvant chemotherapy for breast cancer","volume":"23","author":"Chen","year":"2026","journal-title":"Cancer Biol Med"},{"key":"B106","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.tjog.2025.06.008","article-title":"Ct-based radiomics analysis for prediction of response to neoadjuvant chemotherapy in breast cancer: A systematic review","volume":"65","author":"Huang","year":"2026","journal-title":"Taiwanese J Obstetrics Gynecology"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2018.03.041","article-title":"Chemoresistance evolution in triple-negative breast cancer delineated by single-cell sequencing","volume":"173","author":"Kim","year":"2018","journal-title":"Cell"},{"key":"B108","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.ccell.2023.12.012","article-title":"Single-cell and spatial profiling identify three response trajectories to pembrolizumab and radiation therapy in triple negative breast cancer","volume":"42","author":"Shiao","year":"2024","journal-title":"Cancer Cell"},{"key":"B109","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1038\/s41698-025-01012-6","article-title":"Machine learning model for predicting tertiary lymphoid structures and treatment response in triple-negative breast cancer","volume":"9","author":"Lin","year":"2025","journal-title":"NPJ Precis Oncol"},{"key":"B110","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1038\/s41416-024-02917-y","article-title":"Heterogeneity of tertiary lymphoid structures predicts the response to neoadjuvant therapy and immune microenvironment characteristics in triple-negative breast cancer","volume":"132","author":"Wang","year":"2025","journal-title":"Br J Cancer"},{"key":"B111","doi-asserted-by":"publisher","first-page":"118340","DOI":"10.1016\/j.ejmech.2025.118340","article-title":"Drug repurposing identifies novel Wee1 kinase inhibitors for triple negative breast cancer therapeutics","volume":"302","author":"Pillai","year":"2025","journal-title":"Eur J Med Chem"},{"key":"B112","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1186\/s12951-025-03569-7","article-title":"A gsh-consuming polymeric nanoparticles drives ferroptosis amplification and combines chemotherapy to amplify breast cancer treatment","volume":"23","author":"Pei","year":"2025","journal-title":"J Nanobiotechnol"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202503138","article-title":"Machine learning-enhanced nanoparticle design for precision cancer drug delivery","volume":"12","author":"Wang","year":"2025","journal-title":"Adv Sci"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.3390\/ph18070981","article-title":"From lab to clinic: How artificial intelligence (AI) is reshaping drug discovery timelines and industry outcomes","volume":"18","author":"Dermawan","year":"2025","journal-title":"Pharmaceuticals"},{"key":"B115","doi-asserted-by":"publisher","first-page":"100102","DOI":"10.1016\/j.pharmr.2025.100102","article-title":"Leading ai-driven drug discovery platforms: 2025 landscape and global outlook","volume":"78","author":"Dharmasivam","year":"2025","journal-title":"Pharmacol Rev"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1021\/acs.analchem.5c01864","article-title":"Exploring site-specific n6-methyladenosine modifications as new cancer biomarkers via sers-based single-cell assay and histopathological imaging","volume":"97","author":"Sun","year":"2025","journal-title":"Anal Chem"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-025-01098-8","article-title":"Radiomics Quality Score 2.0: what changed from version 1.0 and why it matters","volume":"23","author":"McGale","year":"2026","journal-title":"Nat Rev Clin Oncol"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.3390\/s26031039","article-title":"Image quality standardization in radiomics: A systematic review of artifacts, variability, and feature stability","volume":"26","author":"Felicetti","year":"2026","journal-title":"Sensors (Basel)"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16152668","article-title":"Impact of preprocessing parameters in medical imaging-based radiomic studies: A systematic review","volume":"16","author":"Trojani","year":"2024","journal-title":"Cancers (Basel)"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0318899","article-title":"When access \u2260 acceptance: How clinical specialty demands shape mutual recognition on medical examination\/test result reuse in Chinese hospitals: A study on a pilot province of China's medical digital reform","volume":"20","author":"Song","year":"2025","journal-title":"PloS One"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.3390\/healthcare13172154","article-title":"Explainable AI in clinical decision support systems: A meta-analysis of methods, applications, and usability challenges","volume":"13","author":"Abbas","year":"2025","journal-title":"Healthcare"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1177\/15330338261434649","article-title":"Overcoming the black box challenge: Building trust in artificial intelligence algorithms in oncology","volume":"25","author":"Alum","year":"2026","journal-title":"Technol Cancer Res Treat"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmpb.2026.109293","article-title":"Explainable machine learning framework for the molecular classification of triple negative breast cancer","volume":"279","author":"L","year":"2026","journal-title":"Comput Methods Programs BioMed"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.3389\/fbinf.2026.1827014","article-title":"An integrative machine learning, explainable AI, molecular simulation, and cytotoxicity validation framework for the discovery of selective SIRT1 inhibitors against triple negative breast cancer","volume":"6","author":"Sharma","year":"2026","journal-title":"Front Bioinf"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-026-10884-y","article-title":"The Virtual Tissues foundation model resolves spatial proteomics across scales","author":"Wenckstern","year":"2026","journal-title":"Nature"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2026.1834128","article-title":"Artificial intelligence for triple-negative breast cancer from imaging to multi-omics","volume":"16","author":"Peng","year":"2026","journal-title":"Front Oncol"},{"key":"B127","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s13058-025-01983-1","article-title":"Decoding breast cancer imaging trends: The role of AI and radiomics through bibliometric insights","volume":"27","author":"Wu","year":"2025","journal-title":"Breast Cancer Res"},{"key":"B128","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1177\/09287329251362602","article-title":"Bibliometric analysis of research on artificial intelligence applications in breast cancer diagnosis","volume":"34","author":"Ekinci","year":"2026","journal-title":"Technol Health Care"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1097\/JS9.0000000000001799","article-title":"Global biomarker trends in triple-negative breast cancer research: A bibliometric analysis","volume":"110","author":"Wang","year":"2024","journal-title":"Int J Surg"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1097\/JS9.0000000000001586","article-title":"Research hotspots and frontiers of neoadjuvant therapy in triple-negative breast cancer: A bibliometric analysis of publications between 2002 and 2023","volume":"110","author":"Yang","year":"2024","journal-title":"Int J Surg"},{"key":"B131","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1007\/s12672-025-03426-x","article-title":"Antibody-drug conjugates in triple-negative breast cancer (2010-2024): A bibliometric analysis of global trends and clinical translation","volume":"16","author":"Li","year":"2025","journal-title":"Discover Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1912317\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T04:36:41Z","timestamp":1790224601000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1912317\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,24]]},"references-count":131,"alternative-id":["10.3389\/fonc.2026.1912317"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1912317","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,24]]},"article-number":"1912317"}}